Get notified when INDP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report includes an explanatory paragraph expressing substantial doubt regarding the Company's ability to continue as a going concern.
- No Active Clinical Programs (new) — The company has discontinued all clinical development and has no active programs, eliminating its primary value driver.
- Nasdaq Delisting Risk (new) — The company faces potential delisting from Nasdaq if it fails to meet continued listing standards, which could severely impact liquidity.
- Dilution (new) — New investors face immediate dilution of $0.50 per share, paying $1.14 for shares with a net tangible book value of only $0.64.
Indaptus Therapeutics launches up to $100M at-the-market offering at $1.14/share
Filed August 31, 2026 · ~1 min read
Key Changes
-
high
Indaptus is offering up to $100 million of common stock via an at-the-market program with H.C. Wainwright, paying a 3% placement fee.
The Offering verify on EDGAR → -
high
The company has no active clinical programs after discontinuing the Decoy20 Combination Study and is evaluating strategic alternatives.
Risk Factors verify on EDGAR → -
high
Auditor Haskell & White's report includes a going-concern explanatory paragraph expressing substantial doubt about the company's ability to continue.
Experts view on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ESTC 10-Q) is open in full — no account needed.
Partner
Trade INDP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify